Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Haematologica. 2020 Dec 1;105(12):2879-2882. doi: 10.3324/haematol.2019.240374.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Boron Compounds
  • Bortezomib / therapeutic use
  • Dexamethasone / therapeutic use
  • Glycine / analogs & derivatives
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / drug therapy
  • Stem Cell Transplantation
  • Thalidomide / therapeutic use
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Boron Compounds
  • Thalidomide
  • Bortezomib
  • ixazomib
  • Dexamethasone
  • Glycine